AVITA Medical, Inc. has announced the exercise of warrants by Perceptive Credit Holdings V, LP and OrbiMed Royalty & Credit Opportunities IV, LP. This event is significant as it reflects the company's ongoing financial strategies and its ability to secure additional capital through these exercises.

On November 13, 2026, AVITA Medical lodged filings on the Australian Securities Exchange (ASX) disclosing the exercises of these previously reported warrants. Perceptive exercised a warrant for 150,000 shares, while OrbiMed exercised a warrant for 409,661 shares. The exercises were completed via cashless transactions, resulting in the issuance of 119,375 shares to Perceptive and 148,158 shares to OrbiMed.

Background

AVITA Medical, Inc. operates in the surgical and medical instruments and apparatus sector, specifically focusing on innovative solutions in the medical field. The company is listed on the Nasdaq under the ticker symbol RCEL and also trades on the OTC market under AVHHL. It has been actively filing various reports with the SEC, including recent 8-K and 10-Q forms.

What the Filing Says

The filing states, "Perceptive exercised the warrant certificate issued by the Company to Perceptive on June 5, 2026... OrbiMed exercised the warrant certificate issued by the Company to OrbiMed on October 18, 2023." This indicates the company's proactive approach in managing its financial obligations and securing necessary funding.

Impact

This development may affect AVITA's shareholders and potential investors as the company continues to navigate its financial landscape. The issuance of shares through warrant exercises can dilute existing shares but also provides the company with much-needed capital to fund its operations and growth initiatives.

What's Next

The filing does not specify what happens next regarding the use of the capital raised through these exercises. However, it indicates that AVITA Medical is actively engaged in financial maneuvers that could enhance its market position.